Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer
Babu S, Horowitz M, Delgado-Coka L, Roa-Peña L, Akalin A, Escobar-Hoyos L, Shroyer K. Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer. Pathology - Research And Practice 2024, 263: 155643. PMID: 39413460, DOI: 10.1016/j.prp.2024.155643.Peer-Reviewed Original ResearchNon-small cell lung cancerLung squamous cell carcinomaNegative prognostic biomarkerCell lung cancerSquamous cell carcinomaPancreatic ductal adenocarcinomaPrognostic biomarkerCell carcinomaMultiplex immunohistochemistryPrognostic accuracyDuctal adenocarcinomaLung cancerPrimary lung squamous cell carcinomaHead and neck squamous cell carcinomaNeck squamous cell carcinomaImpact treatment decisionsClinicopathological factorsClinicopathological variablesOverall prognosisPulmonary adenocarcinomaSolid tumorsNon-smallSurvival differencesPrognostic dataCo-testingPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXKeratin 17 modulates the immune topography of pancreatic cancer
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton C, Hasan M, Babu S, Fassler D, Oentoro J, Bai J, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos L, Shroyer K. Keratin 17 modulates the immune topography of pancreatic cancer. Journal Of Translational Medicine 2024, 22: 443. PMID: 38730319, PMCID: PMC11087249, DOI: 10.1186/s12967-024-05252-1.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaCD8+ T cellsT cellsK17 expressionCell carcinomaPatient survivalMolecular subtypes of pancreatic ductal adenocarcinomaIntratumoral CD8+ T cellsSpatial distribution of T cellsKeratin 17CD8+ T cell abundanceImmune responseSubtype of pancreatic ductal adenocarcinomaCervical squamous cell carcinomaAssociated with decreased numbersCD16+ macrophagesTumor-intrinsic variablesDistribution of T cellsLymph node statusSquamous cell carcinomaBasal cell carcinomaCD163+ macrophagesT cell abundanceImmune cell responsesImmunotherapeutic opportunitiesKeratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Delgado-Coka L, Roa-Peña L, Babu S, Horowitz M, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Akalin A, Jiang W, Larson B, Hendifar A, Picozzi V, Choi M, Shroyer K, Escobar-Hoyos L. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal Of Clinical Pathology 2024, 162: 314-326. PMID: 38642081, PMCID: PMC11369068, DOI: 10.1093/ajcp/aqae038.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPredictive biomarkersDuctal adenocarcinomaK17 expressionKeratin 17Gemcitabine-based therapyGemcitabine-based chemotherapyBasal molecular subtypeTumor mutation statusResponse to chemotherapyPancreatic ductal adenocarcinoma cellsThreshold of expressionChemotherapeutic regimensAdvanced-stageClinicopathological variablesMutation statusPrognostic stratificationMolecular subtypesShorter survivalLonger survivalFormalin-fixedImmunohistochemical testsPredictive valuePatientsTherapeutic interventions